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Abstract
Background: Topical NSAIDs have been proven to relieve the symptoms of osteoarthritis (OA)
in short-term studies (2 weeks). To justify its chronic use, efficacy of a topical NSAID over a longer
term of study should be demonstrated. The efficacy and safety of a topical diclofenac solution over
a 6-week treatment course in symptomatic primary OA of the knee was investigated.
Methods: 216 men and women, age 40–85 years, with radiologically confirmed primary OA of the
knee and a flare of pain at baseline following discontinuation of prior therapy were enrolled into
this double-blind study. Participants applied either a topical diclofenac solution (Pennsaid®) or
vehicle control solution (carrier with no diclofenac); 40 drops 4 times daily directly to the painful
knee(s), without massage, for 6 weeks. Pre-planned primary efficacy outcome measures included
the core continuous variables pain relief and improved physical function measured by the Western
Ontario and McMaster Universities (WOMAC) LK3.1 OA Index, and improved patient global
assessment (PGA). Secondary efficacy measure was reduced stiffness. Safety assessments included
adverse events and vital signs.
Results: The topical diclofenac group had a significantly greater mean change in score (final minus
baseline) compared to the vehicle control group for pain (-5.2 vs. -3.3, p = 0.003), physical function
(-13.4 vs. -6.9, p = 0.001), PGA (-1.3 vs. -0.7, p = 0.0001) and stiffness (-1.8 vs. -0.9, p = 0.002). The
mean difference between treatment arms (95% confidence interval [CI]) was 1.9 (0.7 to 3.2), 6.5
(2.5 to 10.5), 0.6 (0.2 to 0.9), and 0.9 (0.3 to 1.4), respectively. Safety analyses showed that topical
diclofenac caused skin irritation, mostly minor local skin dryness, in 42/107 (39%), leading to
discontinuation of treatment in 5/107 (5%) participants.
Conclusion: This topical diclofenac solution demonstrated relief at 6 weeks of the symptoms of
primary osteoarthritis of the knee.
Background
Meta-analysis of previous trials of topical non-steroidal
anti-inflammatory drugs (NSAIDs) concluded that they
effectively treat the pain of acute soft tissue injuries [1]
and chronic musculoskeletal conditions [2,3]. Current
evidence-based recommendations for the management of
osteoarthritis (OA) support the use of topical NSAIDs and
rubefacients [4-6] as a therapeutic option potentially with
fewer gastrointestinal risks than oral NSAIDs [7]. How-
ever, a recent critical meta-analysis concluded that claims
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of pain relief in OA by currently available topical NSAIDs
are supported by only a limited number of randomised
controlled trials of small size and brief duration, with no
data demonstrating efficacy beyond 2 weeks [8].
In this report, we present the efficacy and safety results
from a 6-week controlled trial using a newer topical
diclofenac solution in knee OA. Effect size data and
number-needed-to-treat (NNT) are presented, facilitating
comparison with the previously reviewed data.
Methods
Participants and inclusion/exclusion criteria
This study was conducted from November 1999 to August
2000, at 17 medical centres across central Canada, follow-
ing approval by a central ethics review board (Integrated
Research Incorporated, Ethics Review Committee, Mon-
treal, QC). Participants were recruited from the physi-
cian's private practice or the surrounding community. At
the screening visit, after providing written, informed con-
sent, each participant underwent a screening interview
and was eligible to proceed to washout if all inclusion cri-
teria and no exclusion criteria were met.
Inclusion criteria specified men and non-pregnant
women, age 40–85 years, with primary OA of at least one
knee, and a flare of pain after withdrawal of prior therapy
with either an oral NSAID or acetaminophen (used at
least 3 days per week during the previous month). Primary
OA was defined by deterioration and abrasion of articular
cartilage (joint space narrowing) or formation of new
bone (osteophytes) at the joint surface of the knee
(medial tibio-femoral, lateral tibio-femoral or patello-
femoral), demonstrated on a radiological examination
carried out within the previous 3 months [9]. Pain was
measured by the Western Ontario and McMaster Univer-
sities LK3.1 OA Index (WOMAC) 5-item pain subscale,
each item scored on a 5-point Likert scale (none = 0; mild
= 1; moderate = 2; severe = 3; extreme = 4) [10]. Pain was
scored at the screening visit, following which prior ther-
apy was withdrawn. The patient scored the pain again at
the baseline visit. A flare was defined as an increase in
total pain subscale score of at least 2 and at least 25%,
with a baseline total pain score of at least 6 (out of a pos-
sible 20), and a score of ≥2 (out of a possible 4) on at least
one of the 5 items in the WOMAC pain subscale.
Participants were excluded if they had secondary arthritis
related to systemic inflammatory arthritis (including
rheumatoid arthritis, psoriatic arthritis, post-infectious
arthritis and metabolic arthritis, traumatic arthritis or sur-
gical joint replacement); corticosteroid use: (a) oral corti-
costeroid within the previous 14 days, or (b)
intramuscular corticosteroid within 30 days, or (c) intra-
articular corticosteroid into the study knee within 90 days,
or (d) intra-articular corticosteroid into any other joint
within 30 days, or (e) topical corticosteroid at the site of
application within 14 days; intra-articular viscosupple-
mentation (e.g., Synvisc®) into the study knee in the pre-
ceding 90 days; ongoing use of prohibited medication
including NSAID, other oral analgesic, muscle relaxant, or
low-dose antidepressant for any chronic pain manage-
ment; ongoing use of glucosamine or chondroitin (unless
used continuously for 90 days prior to study entry); sensi-
tivity to diclofenac, acetylsalicylic acid (ASA) or any other
NSAID, acetaminophen, dimethyl sulphoxide, propylene
glycol, glycerine or ethanol; clinically-active renal, hepatic
or peptic ulcer disease; history of alcohol or drug abuse;
lactation; concomitant skin disease at the application site;
current application for disability benefits on the basis of
knee osteoarthritis; fibromyalgia; other painful or disa-
bling condition affecting the knee; or participation in
another investigational drug trial in the previous 30 days.
Interventions
At the baseline visit, all patients that met the final entry
criterion of a flare of pain were randomly assigned to
receive one of two treatments: (a) topical diclofenac solu-
tion (Pennsaid®; Dimethaid Research Inc.), consisting of
1.5% (w/w) diclofenac sodium in a patented carrier con-
taining dimethyl sulphoxide (45.5%, w/w), propylene
glycol, glycerine, ethanol and water, or (b) vehicle control
solution, consisting of the complete carrier (including
dimethyl sulphoxide, 45.5% w/w) but no diclofenac. Par-
ticipants applied a dose of 40 drops of study solution
(about 1.3 mL) to the affected knee 4 times daily for up to
6 weeks. The participant was instructed to apply 10 drops
of solution to each side of the knee (front, back, medial
and lateral) either dripped directly onto the knee or first
into the hand, and then spread over the site without mas-
sage. Compliance was verified by weighing the solution
bottles at each visit. If the other knee was painful at any
time during the study, it was treated and evaluated for
safety, but efficacy analysis was performed on only the
study knee – the one with the greater baseline pain score
(or the dominant knee if both had the same score). Con-
sumption of acetaminophen (up to four 325-mg tablets
per day) was permitted for residual knee or other body
pain throughout the treatment period, but not during the
washout period prior to baseline assessment or during the
week prior to final assessment at week 6. ASA (≤ 325 mg/
day) was permitted for cardiovascular prophylaxis.
Outcome measures
The primary outcome measures were defined as the
change from baseline to final assessment of the study knee
in the 3 core continuous variables [11] pain and physical
function, assessed using the WOMAC subscales, and
patient global assessment (PGA). There was no intermedi-
ate assessment of efficacy. The WOMAC is a validatedBMC Musculoskeletal Disorders 2005, 6:44 http://www.biomedcentral.com/1471-2474/6/44
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questionnaire [12] consisting of 24 questions (5 on pain,
17 on physical function and 2 on stiffness), each scored
on a 5-point Likert scale (see Participants). The PGA ques-
tion asked: "How has the osteoarthritis in your study joint
been over the last 48 hours?" and was scored on a Likert
scale (very good = 0; good = 1; fair = 2; poor = 3; very poor
= 4). This question focuses on the treated site, unlike a
PGA in an oral NSAID trial that can probe the non-signal
joints. Secondary measure was change in stiffness. Ancil-
lary measures defined a posteriori were pain on walking –
the first question of the WOMAC pain subscale (referred
to as 'use-related pain' [13]) – and the following dichoto-
mous variables: 50% improvement in pain [3]; final PGA
score of "good" or "very good" [3]; and response based on
OMERACT-OARSI responder criteria [14] (a responder is
defined as a participant with ≥ 50% improvement in pain
or function that was ≥ 20% of the scale, or ≥ 20%
improvement in at least two of pain, function or PGA that
was ≥ 10% of the scale).
Safety analyses
Safety was assessed during all clinic visits (weeks 3 and 6)
and telephone 'visits' (weeks 1 and 5). Safety variables
included adverse events, application-site dermatological
reactions and vital signs. Adverse events were identified
using open-ended questions and a checklist covering
common oral NSAID side effects. Dermatological assess-
ment of the knee was based on a standard scale [15] and
any abnormality was recorded as an adverse event. All
adverse events were categorised according to Coding Sym-
bols for Thesaurus of Adverse Reaction Terms (COSTART)
[16]. Laboratory assessment was not done.
Sample size
Based on a power of 80% and a Type I error rate of α =
0.052-tailed, a sample size of 80 participants per group was
required to detect an estimated important difference of 2
between the treatment arms, in the change in WOMAC
pain dimension score from baseline to final (with stand-
ard deviation of 4.5). A total sample size of 200 partici-
pants (100 per treatment group) was specified in the
protocol, which allowed for a non-evaluable rate of up to
20%.
Randomisation and blinding
The study kits were prepared, labelled and numbered
according to a computer-generated randomisation sched-
ule created by an outside consultant using a randomly
chosen block size of 4 or 6. They were shipped to the sites
in multiples of complete blocks to ensure that a balanced
number of participants was assigned to the two treatment
arms within each site. As a participant qualified for study
entry at the baseline visit, the investigator assigned him/
her the next randomisation number in a sequential man-
ner. The randomisation schedule was concealed from the
investigators, their support staff, study participants and
the sponsor's clinical research personnel, until final data
lock. Except for the individual participant identification
number on the label, the two study solutions were identi-
cal clear, colourless liquids packaged in opaque bottles.
Statistical analysis
Safety analyses were performed on all randomised partic-
ipants who received at least one dose of study solution.
There was no imputation of missing safety data. Efficacy
analyses were performed on an intent-to-treat (ITT)
group, defined as a subset of all randomised participants
who met critical inclusion criteria (primary OA by history,
an abnormal radiological study, and any degree of knee
pain), as per ICH guidelines [17]. For any missing efficacy
data in the ITT analysis, the last observation was carried
forward. A per-protocol group was defined based on
stricter adherence to study conduct, including require-
ment for a moderate flare of knee pain (see Participants)
and treatment continuing for at least 40 days.
Baseline demographic and clinical variables were ana-
lysed by Chi-square or Student's t-Test. Adverse event inci-
dence was analysed by Chi-square or Fisher's Exact Test.
Continuous variables (WOMAC dimensions, PGA and
pain on walking) were analysed by ANCOVA with base-
line score as the covariate without adjustment for testing
secondary/alternative objectives. The dichotomous varia-
bles were analysed by Chi-square test. All statistical tests
were two-sided and were performed at the 0.05 level of
significance.
Results
Participant flow
Two hundred and sixteen participants were randomised to
treatment with either topical diclofenac (n = 107) or vehi-
cle control (n = 109). All participants received their allo-
cated intervention. More participants in the topical
diclofenac group (86 [80%]) completed the entire 6-week
treatment period compared to the vehicle control group
(70 [64%]; p = 0.008). Discontinuation rate due to an
adverse event was similar in both groups. Dropout due to
lack of effect was lower for topical diclofenac (8 [7.5%])
compared to vehicle control (18 [16.5%]; p = 0.041). No
participant was lost to follow-up (Fig. 1).
Baseline demographic and clinical characteristics
No significant difference was found between treatment
groups in baseline demographic and clinical characteris-
tics (Table 1). The mean (SD) screening and baseline pain
scores were 8.2 (2.7) and 13.0 (3.2) in the topical
diclofenac group versus 8.3 (3.0) and 12.8 (3.1) in the
vehicle control group (12.9 [3.2] overall). Most partici-
pants treated both knees, either from baseline or by the
end of the trial.BMC Musculoskeletal Disorders 2005, 6:44 http://www.biomedcentral.com/1471-2474/6/44
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Flow of participants Figure 1
Flow of participants.BMC Musculoskeletal Disorders 2005, 6:44 http://www.biomedcentral.com/1471-2474/6/44
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Mean (SD) duration of treatment in the topical diclofenac
group was 38.2 (9.9) days versus 34.4 (12.5) days in the
vehicle control group (p = 0.013). Compliance with the
dosing regime was 83.1 % and 84.5% for the topical
diclofenac and vehicle control groups, respectively. No
significant difference was noted in the mean (SD) con-
sumption of rescue acetaminophen tablets per day
between the topical diclofenac (0.9 [0.9]) and vehicle
control groups (1.1 [1.0]; p = 0.079).
Efficacy analyses
Four of 216 randomized participants were not included in
the ITT analysis group because they violated major entry
criteria: 2 participants lacked radiological confirmation of
OA (no radiological examination for one participant and
a normal examination for the other), and 2 participants
had secondary OA (related to osteochondroma). Inclu-
sion of these participants yielded the same results in a sub-
sequent re-analysis (data not shown).
Planned analyses
There was a significantly greater improvement in score
with topical diclofenac compared to vehicle control
(Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical func-
tion (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p =
0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002) Analysis of
the per protocol group of 128 participants confirmed the
statistical superiority of topical diclofenac over vehicle
control for the primary and secondary outcome measures
(p < 0.01; data not shown).
A posteriori analyses
There was a significantly greater improvement in score
with topical diclofenac compared to vehicle control
(Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).
The response rate for at least a 50% reduction in pain
(Table 3) was significantly greater following topical
diclofenac treatment compared to vehicle control (46/105
[43.8%] vs. 27/107 [25.2%]; p = 0.004). The topical
diclofenac group had a significantly greater number of
participants with good or very good PGA response (43.8%
vs. 16.8%; p <0.0001) compared to the vehicle control
group and of OMERACT-OARSI responders (65.7% vs.
49.5%; p = 0.017).
Adverse events
The major adverse effect reported was dry skin at the
application site, occurring in 42/107 (39.3%) and 23/109
(21.1%; p = 0.004) of topical diclofenac and vehicle
control participants, respectively (Table 4). A skin-related
adverse event led to discontinuation of only 5 participants
in the topical diclofenac group. All skin reactions resolved
promptly upon withdrawal of treatment. Abdominal pain
and dyspepsia each were reported in 4 [3.7%] participants
Table 1: Baseline demographic and clinical characteristics of treatment groups
Topical diclofenac (n = 107) Vehicle control (n = 109)
Age (years) 65.0 (11.0) 64.6 (10.9)
Women, number (%) 56 (52.3) 66 (60.6)
Race/ethnicity, number (%)
White 88 (82.2) 91 (83.5)
Black 8 (7.5) 3 (2.8)
Oriental 3 (2.8) 2 (1.8)
Other 8 (7.5) 13 (11.9)
Weight (kg) 89.9 (18.1) 86.5 (17.3)
Height (m) 1.65 (0.11) 1.65 (0.10)
Heart rate (bpm) 74.1 (10.0) 74.3 (9.1)
Systolic blood pressure (mm Hg) 137.6 (16.3) 133.6 (15.6)
Diastolic blood pressure (mm Hg) 81.4 (9.1) 79.7 (8.7)
Total x-ray score* 7.7 (5.4) 7.0 (5.0)
Screening pain score 8.2 (2.7) 8.3 (3.0)
Baseline† pain score 13.0 (3.2) 12.8 (3.1)
Baseline† physical function score 40.7 (11.9) 40.4 (11.2)
Baseline† stiffness score 5.2 (1.5) 5.2 (1.5)
Patient global assessment score‡ 3.1 (0.8) 3.2 (0.8)
Participants treating two knees at baseline, number (%) 64 (59.8) 70 (64.2)
Participants treating two knees at final, number (%) 84 (78.5) 89 (81.7)
Data are presented as mean (SD) unless otherwise indicated.
*Total score of joint space narrowing, marginal osteophytes formation and subchondrial sclerosis for each knee compartment (medial, lateral, 
patello-femoral); maximum score possible was 27.
†After washout of prior therapy; pain scale ranged from 0 (no pain) to 20 (extreme pain); physical function scale ranged from 0 (no difficulty) to 68 
(extreme difficulty); stiffness scale ranged from 0 (no stiffness) to 8 (extreme stiffness).
‡Patient global assessment was measured using a Likert scale, ranging from 0 (very good) to 4 (very poor).BMC Musculoskeletal Disorders 2005, 6:44 http://www.biomedcentral.com/1471-2474/6/44
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in the topical diclofenac group compared to 1 [0.9%] par-
ticipant in the vehicle control group, but this difference
was not significant (p = 0.21).
Discussion
Published guidelines have incorporated topical NSAIDs
as recommended treatment for OA of the knee [4-6].
However, there has been controversy surrounding the
adequacy of data supporting their benefit beyond 2 weeks
[2,3,8,18]. Moreover, the studies identified in these meta-
analyses generally did not conform to current standards
for OA trial design [11,19]. In contrast, the present trial
utilized standardized radiological and clinical entry crite-
ria and measured efficacy with validated outcome meas-
ures. Baseline pain score was substantial; mean (SD) score
was 12.9 (3.2) out of a maximum of 20, indicating a flare
of pain following withdrawal of prior therapy. Analysis of
all of the primary and secondary measures demonstrated
that treatment with this topical diclofenac solution
relieved the symptoms of primary knee OA at 6 weeks in
this study population. Two other recently published trials
using this topical diclofenac solution showed it to be
superior to vehicle control and/or placebo; a 4-week, non-
flare trial of 248 participants [20] and a 12-week, flare trial
of 326 participants [21]. As with most NSAID trials, the
subject population in this study was selected by the inclu-
sion criterion of a flare of pain, which demonstrates the
potential to respond to NSAID/analgesic. In clinical
practice, an individual not taking an analgesic may have
considered previous NSAID therapy ineffective, in which
case s/he would not be expected to respond to topical
diclofenac. However, where an individual is intolerant to
oral NSAID, one may consider topical diclofenac as a
treatment option.
Comparison of efficacy results from independent trials
with various treatments is facilitated by the introduction
of benchmark determinants that are mathematically
derived from the experimental raw data, such as effect size
[22] for improvement of a continuous variable (e.g. "How
much did the patient's pain improve, relative to pla-
cebo?"). We calculated an effect size (95% CI) of 0.41
(0.14 to 0.68) for pain relief, 0.44 (0.16 to 0.71) for
improved physical function and 0.34–0.47 for improved
measures of PGA, stiffness and pain on walking (Table 2).
In contrast, Lin et al. [8] calculated a pooled effect size for
Table 2: Efficacy evaluation of the continuous variables
Efficacy variable Treatment 
group
NB a s e l i n e  
score, mean 
(SD)
Change in score 
mean (SD)
Mean difference 
in change 
(95% CI)
P-value Effect size 
(95% CI)
Pain Topical diclofenac 105 13.0 (3.1) -5.2 (5.0) 1.9 (0.7 to 3.2) 0.003 0.41 (0.14 to 0.68)
Vehicle control 107 12.7 (3.2) -3.3 (4.3)
Physical function Topical diclofenac 105 40.9 (11.9) -13.4 (16.3) 6.5 (2.5 to 10.5) 0.001 0.44 (0.16 to 0.71)
Vehicle control 107 40.3 (11.3) -6.9 (13.2)
Patient global assessment Topical diclofenac 105 3.1 (0.8) -1.3 (1.3) 0.6 (0.2 to 0.9) 0.0001 0.47 (0.19 to 0.74)
Vehicle control 107 3.2 (0.7) -0.7 (1.1)
Stiffness Topical diclofenac 105 5.3 (1.4) -1.8 (2.1) 0.9 (0.3 to 1.4) 0.002 0.43 (0.15 to 0.70)
Vehicle control 107 5.2 (1.5) -0.9 (2.0)
Pain on walking Topical diclofenac 105 2.7 (0.8) -1.2 (1.2) 0.4 (0.1 to 0.7) 0.014 0.34 (0.07 to 0.61)
Vehicle control 107 2.7 (0.8) -0.8 (1.1)
Table 3: Efficacy evaluation of the dichotomous variables
Efficacy variables Treatment group N Number (%) of 
participants
p-value Number-needed-to-
treat (95% CI)
50% reduction in pain Topical diclofenac 105 46 (43.8) 0.004 5 (3–17)
Vehicle control 107 27 (25.2)
OMERACT-OARSI responder* Topical diclofenac 105 69 (65.7) 0.017 6 (3–33)
Vehicle control 107 53 (49.5)
Good or very good PGA response Topical diclofenac 105 46 (43.8) <0.0001 4 (3–7)
Vehicle control 107 18 (16.8)
*A responder is defined as a participant with ≥ 50% improvement in pain or function that was ≥ 20% of the scale, or ≥ 20% improvement in at least 
two of pain, function or patient global assessment that was ≥ 10% of the scale.BMC Musculoskeletal Disorders 2005, 6:44 http://www.biomedcentral.com/1471-2474/6/44
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pain relief of 0.04 (essentially no effect) in 3 placebo-con-
trolled topical NSAID trials of 4 weeks duration. A meta-
analysis of 23 oral NSAID trials for OA knee, lasting 2–13
weeks, reported a pooled effect size of 0.32 for pain reduc-
tion and 0.29 for improving physical function [23].
Another meta-analysis of 14 OA trials found a pooled
effect size of 0.37 for pain reduction with oral NSAIDs and
0.44 for coxibs [24]. Zhang et al. [25], using data from 2
oral NSAID studies of 6–12 weeks duration, calculated a
pooled effect size for OA pain reduction of 0.34.
Efficacy of a treatment is being expressed increasingly as a
dichotomous result, e.g. "Did the patient's pain improve
by 50%; yes or no?". We derived the response rate for each
dichotomous variable from our raw data, and demon-
strated the superiority of topical diclofenac over vehicle
control for 50% reduction in pain, achieving a good or
very good final PGA response, and 'response' by OMER-
ACT-OARSI criteria (Table 3). The benchmark determi-
nant for comparing dichotomous efficacy results of
various treatments is the number-needed-to-treat (NNT)
[26]. We calculated a NNT between 4 and 6, depending
upon the variable (Table 3). In their meta-analysis of
topical NSAIDs, Mason et al. [3] cited 5 placebo-control-
led trials of short duration for OA knee pain – 8 days (1
trial), 14 days (3 trials), and 28 days (1 trial). Their defi-
nition of clinical success, representing approximately a
50% reduction of pain, was estimated using patient or
physician global assessment as the outcome measure (4
trials and 1 trial, respectively). They calculated a NNT of
5.3.
Few oral NSAID studies have reported dichotomous data.
Osiri et al. [26] reported a NNT for pain improvement of
4.4 with etodolac and 3.8 with tenoxicam. Defining
improvement as an increase of at least 2 grades (on a 0–5
scale) in the patient's global rating of arthritis, Edwards et
al. [27] reported a NNT of 11–13 for valdecoxib treatment
of OA.
The OMERACT-OARSI initiative used a consensus
approach to derive dichotomous 'responder' criteria [14].
Through their vast meta-analysis of suitable trials, the
authors found that for trials of oral NSAIDs vs. placebo
the responder rates were 65.4% and 45.9% respectively.
Responder rates of 60–65% have been reported for 13-
week treatment of OA with celecoxib and lumiracoxib,
with placebo responder rates of 49–53% [28,29]. The
OMERACT-OARSI initiative did not look at topicals but
we applied its criteria to this study and found a responder
rate for topical diclofenac of 65.7% with a placebo
responder rate of 49.5%, similar to their oral NSAID data.
Table 4: Number (%) of adverse events
Adverse Event Topical diclofenac (n = 107) Vehicle control (n = 109)
Gastrointestinal reaction
Abdominal pain 4 (3.7) 1 (0.9)
Constipation 1 (0.9) 1 (0.9)
Diarrhea 1 (0.9) 0
Dyspepsia 4 (3.7) 1 (0.9)
Gastritis 1 (0.9) 0
Melena 0 1 (0.9)
Nausea 1 (0.9) 2 (1.8)
Application-site skin reaction
Dry skin 42 (39.3)* 23 (21.1)
Rash 2 (1.9) 4 (3.7)
Paresthesia 2 (1.9) 2 (1.8)
Pruritus 0 2 (1.8)
Other reaction
Headache 6 (5.6) 10 (9.2)
Halitosis 2 (1.9) 0
Taste Perversion 4 (3.7) 2 (1.8)
*p < 0.01 vs. vehicle controlBMC Musculoskeletal Disorders 2005, 6:44 http://www.biomedcentral.com/1471-2474/6/44
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A caveat in the application of the mathematical bench-
marks, effect size and NNT, is the influence of trial design,
outcome measures and patient population on the appar-
ent magnitude of response to a given treatment. Because
the trials with topical diclofenac were designed according
to the OARSI guidelines, like most recent NSAID and
cyclooxygenase-2 (COX-2) inhibitor studies, such com-
parison of results is reasonable [19]. Although the data
observed for topical diclofenac in this trial are comparable
to other NSAID trials, a direct head-to-head comparison
trial is required to prove equivalency of two treatments. A
previously published 12-week comparative trial of 622
participants with OA knee confirmed the clinical equiva-
lence between topical diclofenac solution and oral
diclofenac [30].
Safety analysis revealed no serious clinical adverse effects
and only minor application-site skin reactions, mostly
skin dryness, following treatment with topical diclofenac.
While dimethyl sulphoxide in the carrier acts as a pene-
trant [31], it also dissolves normal surface oils and leaves
the skin dry. Common skin lubricants may prevent most
application site reactions and any related discontinued
therapy, but such products were not permitted in this trial
in order to detect the maximum potential side effect pro-
file of the study solutions. The low dropout rate due to
skin reactions (5/107 [4.7%] for topical diclofenac) sug-
gests patient acceptance of the overall topical treatment
regime.
The use of a checklist to prompt the patient about possible
adverse events likely yielded a high estimate of the true
incidence of gastrointestinal adverse reactions caused by
topical diclofenac. The report of abdominal pain and dys-
pepsia each in 3.7% of patients is consistent with what
was seen in other published trials of this topical
diclofenac [20,21] and much lower than commonly expe-
rienced with oral NSAIDs or COX-2s [30]. Those other tri-
als included results of laboratory testing and found minor
abnormality of liver enzymes in 2–5%, creatinine in 1%
and haemoglobin in 2% of patients, significantly lower
than with oral diclofenac [30]. This safety profile can be
predicted from the low systemic availability of topically
applied diclofenac. Although the patient applies a daily
dose (40 drops, 4 times a day) of 86 mg of diclofenac to
the knee, the blood level is only 12 ng/mL [31]. The level
reported after oral administration of 50 mg Voltaren® is
1500 ng/mL [32]. Similar improved safety with topical
NSAIDs has been reported previously [33].
Conclusion
Topical diclofenac solution provides 6-week relief of the
symptoms of knee OA. The data in this and previous
reports provide substantial evidence for the efficacy and
safety of topical diclofenac solution in chronic OA.
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